GLUT1 and PKM2 may be useful prognostic predictors in patients with non‑small cell lung cancer following curative R0 resection

Ito,Ryuichi; Yashiro,Masakazu; Tsukioka,Takuma; Izumi,Nobuhiro; Komatsu,Hiroaki; Inoue,Hidetoshi; Yamamoto,Yurie; Nishiyama,Noritoshi

doi:10.3892/ol.2023.13715

GLUT1 and PKM2 may be useful prognostic predictors in patients with non‑small cell lung cancer following curative R0 resection

Authors:
- Ryuichi Ito
- Masakazu Yashiro
- Takuma Tsukioka
- Nobuhiro Izumi
- Hiroaki Komatsu
- Hidetoshi Inoue
- Yurie Yamamoto
- Noritoshi Nishiyama
View Affiliations

Affiliations: Department of Thoracic Surgery, Osaka Metropolitan University, Osaka 545‑8585, Japan, Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: February 10, 2023 https://doi.org/10.3892/ol.2023.13715
Article Number: 129
Copyright: © Ito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer has a poor prognosis despite recent progresses being made regarding its treatment. In addition, there is a paucity of reliable and independent prognostic predictors for non‑small cell lung cancer (NSCLC) following curative resection. Glycolysis is associated with the malignancy and proliferation of cancer cells. Glucose transporter 1 (GLUT1) promotes glucose uptake, whereas pyruvate kinase M2 (PKM2) promotes anaerobic glycolysis. The present study aimed to evaluate the relationship between the expression of GLUT1 and PKM2 and the clinicopathological features of patients with NSCLC, and to identify a reliable prognostic factor for NSCLC following curative resection. Patients with NSCLC who underwent curative surgery were retrospectively enrolled to the present study. GLUT1 and PKM2 expression was assessed using immunohistochemistry. Subsequently, the association between the clinicopathological features of patients with NSCLC and the expression of GLUT1 and PKM2 was assessed. Of the 445 patients with NSCLC included in the present study, 65 (15%) were positive for both GLUT1 and PKM2 expression (G+/P+ group). GLUT1 and PKM2 positivity was significantly associated with sex, absence of adenocarcinoma, lymphatic invasion and pleural invasion. Furthermore, patients with NSCLC in the G+/P+ group presented significantly poorer survival rates than those expressing other markers. G+/P+ expression was significantly associated with poor disease‑free survival. In conclusion, the findings of the present study indicated that the combination of GLUT1 and PKM2 may be considered a reliable prognostic factor for patients with NSCLC following curative resection, especially in patients with stage I NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Abdel-Wahab AF, Mahmoud W and Al-Harizy RM: Targeting glucose metabolism to suppress cancer progression: Prospective of anti-glycolytic cancer therapy. Pharmacol Res. 150:1045112019. View Article : Google Scholar : PubMed/NCBI
5	Lebelo MT, Joubert AM and Visagie MH: Warburg effect and its role in tumourigenesis. Arch Pharm Res. 42:833–847. 2019. View Article : Google Scholar : PubMed/NCBI
6	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
7	Thews O and Riemann A: Tumor pH and metastasis: A malignant process beyond hypoxia. Cancer Metastasis Rev. 38:113–129. 2019. View Article : Google Scholar : PubMed/NCBI
8	Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI
9	Jun YJ, Jang SM, Han HL, Lee KH, Jang KS and Paik SS: Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas. World J Gastroenterol. 17:1866–1873. 2011. View Article : Google Scholar : PubMed/NCBI
10	Grabellus F, Nagarajah J, Bockisch A, Schmid KW and Sheu SY: Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 37:121–127. 2012. View Article : Google Scholar : PubMed/NCBI
11	Luo XM, Zhou SH and Fan J: Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 38:1885–1892. 2010. View Article : Google Scholar : PubMed/NCBI
12	Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG and Soares FA: GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo). 66:965–972. 2011. View Article : Google Scholar : PubMed/NCBI
13	Tan Z, Yang C, Zhang X, Zheng P and Shen W: Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: A pooled analysis of 1665 patients. Oncotarget. 8:60954–60961. 2017. View Article : Google Scholar : PubMed/NCBI
14	Minami K, Saito Y, Imamura H and Okamura A: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer. 38:51–57. 2002. View Article : Google Scholar : PubMed/NCBI
15	Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer. 72:294–302. 2011. View Article : Google Scholar : PubMed/NCBI
16	Osugi J, Yamaura T, Muto S, Okabe N, Matsumura Y, Hoshino M, Higuchi M, Suzuki H and Gotoh M: Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer. Lung Cancer. 88:310–318. 2015. View Article : Google Scholar : PubMed/NCBI
17	Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van der Heijden HF, Rademakers SE, Span PN and Bussink J: Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer. 76:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
18	Jiang L and Deberardinis RJ: Cancer metabolism: When more is less. Nature. 489:511–512. 2012. View Article : Google Scholar : PubMed/NCBI
19	Guo CY, Zhu Q, Tou FF, Wen XM, Kuang YK and Hu H: The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma. BMC Cancer. 19:2892019. View Article : Google Scholar : PubMed/NCBI
20	Rzechonek A, Kaminska A, Mamczur P, Drapiewski A and Budzynski W: Limited clinical significance of dimeric form of pyruvate kinase as a diagnostic and prognostic biomarker in non-small cell lung cancer. Adv Exp Med Biol. 955:51–57. 2017. View Article : Google Scholar : PubMed/NCBI
21	Tirpe AA, Gulei D, Ciortea SM, Crivii C and Berindan-Neagoe I: Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 20:61402019. View Article : Google Scholar : PubMed/NCBI
22	Goswami CP and Nakshatri H: PROGgeneV2: Enhancements on the existing database. BMC Cancer. 14:9702014. View Article : Google Scholar : PubMed/NCBI
23	Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
25	Schuurbiers OCJ, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der Heijden EH, Oyen WJ, Visser EP, Span PN and Bussink J: Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol. 9:1485–1493. 2014. View Article : Google Scholar : PubMed/NCBI
26	Fan C, Yu J, Liu Y, Xu H and Wang E: Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer. Pathol Oncol Res. 18:549–556. 2012. View Article : Google Scholar : PubMed/NCBI
27	Li Z and Zhang H: Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 73:377–392. 2016. View Article : Google Scholar : PubMed/NCBI
28	Masoud GN and Li W: HIF-1α pathway: Role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
29	Sasaki H, Shitara M, Yokota K, Hikosaka Y, Moriyama S, Yano M and Fujii Y: Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Rep. 5:599–602. 2012.PubMed/NCBI
30	Maki Y, Soh J, Ichimura K, Shien K, Furukawa M, Muraoka T, Tanaka N, Ueno T, Yamamoto H, Asano H, et al: Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncol Rep. 29:133–140. 2013. View Article : Google Scholar : PubMed/NCBI
31	Sobue T, Suzuki T, Fujimoto I, Matsuda M, Doi O, Mori T, Furuse K, Fukuoka M, Yasumitsu T, Kuwahara O, et al: Case-control study for lung cancer and cigarette smoking in Osaka, Japan: Comparison with the results from Western Europe. Jpn J Cancer Res. 85:464–473. 1994. View Article : Google Scholar : PubMed/NCBI
32	Yu P, Alves TC, Kibbey RG and Simons M: Metabolic analysis of lymphatic endothelial cells. Methods Mol Biol. 1846:325–334. 2018. View Article : Google Scholar : PubMed/NCBI
33	Jiang H, Zou Y, Zhao J, Li X, Yang S, Zhou X, Mou D, Zhong W and Cai Y: Pyruvate kinase M2 mediates glycolysis in the lymphatic endothelial cells and promotes the progression of lymphatic malformations. Am J Pathol. 191:204–215. 2021. View Article : Google Scholar : PubMed/NCBI
34	Zhang B, Xie Z and Li B: The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene. 689:76–83. 2019. View Article : Google Scholar : PubMed/NCBI
35	Li Z, Yang P and Li Z: The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
36	Li L, Zhang Y, Qiao J, Yang JJ and Liu ZR: Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis. J Biol Chem. 289:25812–25821. 2014. View Article : Google Scholar : PubMed/NCBI
37	Zahra K, Dey T, Ashish Mishra SP and Pandey U: Pyruvate kinase M2 and cancer: The role of PKM2 in promoting tumorigenesis. Front Oncol. 10:1592020. View Article : Google Scholar : PubMed/NCBI
38	Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H and Oda Y: Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Hum Pathol. 45:1610–1617. 2014. View Article : Google Scholar : PubMed/NCBI
39	Cerfolio RJ, Bryant AS, Ohja B and Bartolucci AA: The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 130:151–159. 2005. View Article : Google Scholar : PubMed/NCBI